Axel Haupt

Company: Eli Lilly

Job title: Vice President for Diabetes Clinical Investigation & Insulin & Incretin Research

Seminars:

Tirzepatide for the Treatment of NASH 11:30 am

• Hearing how Tirzepatide shows improvement in NASH biomarkers and relevant metabolic traits in phase 2 and phase 3 trials in patients with T2D • Revealing how Tirzepatide shows profound lowering in liver fat – a phase 3 MRI addendum in T2D • Discovering SYNERGY-NASH: Tirzepatide Phase 2 designRead more

day: Day 1 Stream 3 AM